Axsome Therapeutics (AXSM) Free Cash Flow (2015 - 2026)

Axsome Therapeutics has reported Free Cash Flow for 12 years, with the latest figure at -$20.8 million in Q1 2026.

• Quarterly Free Cash Flow rose 52.37% year-over-year to -$20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$71.0 million (up 40.26% YoY) and the FY2025 annual result came in at -$93.9 million, up 27.04% from the prior year.
• Free Cash Flow fell to -$20.8 million in Q1 2026 per AXSM's latest filing, from -$18.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $988000.0 in Q3 2025 and troughed at -$55.5 million in Q2 2023.
• A 5-year average of -$29.8 million and a median of -$30.2 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow plunged 809.11% in 2024, then jumped 105.28% in 2025.
• Over 5 years, Free Cash Flow stood at -$27.7 million in 2022, then slipped by 9.46% to -$30.4 million in 2023, then climbed by 13.62% to -$26.2 million in 2024, then gained by 28.62% to -$18.7 million in 2025, then retreated by 11.2% to -$20.8 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$20.8 million, -$18.7 million, and $988000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.